Don Hemmavanh

Title: Don Hemmavanh: Innovator in Protein Glycosylation Modulation

Introduction

Don Hemmavanh is a notable inventor based in Worcester, MA (US). He has made significant contributions to the field of biotechnology, particularly in the modulation of protein glycosylation profiles. His innovative approach has implications for the development of recombinant proteins, which are crucial in various therapeutic applications.

Latest Patents

Hemmavanh holds a patent titled "Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins." This patent highlights the importance of protein glycosylation in influencing the structure, function, and pharmacokinetics of recombinant proteins. The research demonstrates that growth media supplemented with metal ions can effectively modulate the glycosylation profile of recombinant proteins expressed in various eukaryotic cell lines. Notably, the use of ferric salts, such as ferric nitrate and ferric citrate, significantly increased the percentage of galactosylated N-glycan species in a concentration-dependent manner, up to 1.0 mM, without adversely affecting cell viability. This innovative method provides an efficient approach to specifically re-target N-glycan glycoform profiles of recombinantly expressed proteins.

Career Highlights

Don Hemmavanh is currently employed at AbbVie Inc., where he continues to advance his research in biotechnology. His work focuses on enhancing the efficacy of recombinant proteins through innovative glycosylation techniques. Hemmavanh's contributions to the field have positioned him as a key figure in the development of biopharmaceuticals.

Collaborations

Hemmavanh has collaborated with esteemed colleagues, including Alane E. Wentz and Joseph G. Matuck. These collaborations have fostered a productive research environment, leading to advancements in the understanding of protein glycosylation.

Conclusion

Don Hemmavanh's innovative work in protein glycosylation modulation represents a significant advancement in biotechnology. His patent and ongoing research at AbbVie Inc. highlight the potential for improved therapeutic proteins through targeted glycosylation strategies.